2.50
Hdl Handle:
http://hdl.handle.net/10541/99760
Title:
Future outlook for growth factors.
Authors:
Scarffe, J Howard
Abstract:
In the future improvements in the efficacy and safety profiles of the various growth factors in clinical use should be achievable through optimization of dosage schedules. The use of combinations of growth factors to provide hemopoietic support should enable considerable advances to be made in the treatment of hematological and non-hematological malignancies. Growth factors, such as granulocyte-macrophage colony stimulating factor may be used not only to maximize neutrophil recovery after myeloablative therapy, but also to mobilize peripheral blood stem cells prior to harvesting by leukapheresis. Growth inhibitory cytokines such as transforming growth factor-beta and macrophage inflammatory protein-1 alpha may be used to protect normal cells in the bone marrow and other sites where dose-limiting toxicities occur. Therefore, in the next few years, the whole approach to chemoradiotherapy will need to be reconsidered in the light of the dose intensification made possible by improved bone marrow support techniques and advances in other areas of supportive care.
Affiliation:
Department of Medical Oncology, Christie Hospital, Withington, Manchester, UK.
Citation:
Future outlook for growth factors. 1993, 4 Suppl 1:27-31 Anticancer Drugs
Journal:
Anti-Cancer Drugs
Issue Date:
May-1993
URI:
http://hdl.handle.net/10541/99760
PubMed ID:
8347854
Type:
Article
Language:
en
ISSN:
0959-4973
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorScarffe, J Howarden
dc.date.accessioned2010-05-24T15:30:47Z-
dc.date.available2010-05-24T15:30:47Z-
dc.date.issued1993-05-
dc.identifier.citationFuture outlook for growth factors. 1993, 4 Suppl 1:27-31 Anticancer Drugsen
dc.identifier.issn0959-4973-
dc.identifier.pmid8347854-
dc.identifier.urihttp://hdl.handle.net/10541/99760-
dc.description.abstractIn the future improvements in the efficacy and safety profiles of the various growth factors in clinical use should be achievable through optimization of dosage schedules. The use of combinations of growth factors to provide hemopoietic support should enable considerable advances to be made in the treatment of hematological and non-hematological malignancies. Growth factors, such as granulocyte-macrophage colony stimulating factor may be used not only to maximize neutrophil recovery after myeloablative therapy, but also to mobilize peripheral blood stem cells prior to harvesting by leukapheresis. Growth inhibitory cytokines such as transforming growth factor-beta and macrophage inflammatory protein-1 alpha may be used to protect normal cells in the bone marrow and other sites where dose-limiting toxicities occur. Therefore, in the next few years, the whole approach to chemoradiotherapy will need to be reconsidered in the light of the dose intensification made possible by improved bone marrow support techniques and advances in other areas of supportive care.en
dc.language.isoenen
dc.subject.meshBone Marrow Transplantation-
dc.subject.meshDrug Administration Schedule-
dc.subject.meshForecasting-
dc.subject.meshGrowth Substances-
dc.subject.meshHumans-
dc.titleFuture outlook for growth factors.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Christie Hospital, Withington, Manchester, UK.en
dc.identifier.journalAnti-Cancer Drugsen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.